摘要
目的探讨HSP的免疫学发病机制。方法采用直接免疫荧光流式细胞分析技术检测HSP患儿急性期外周血单个核细胞CD4+CD30和CD4+CD30Th细胞亚群,多克隆抗体单向免疫扩散法检测血浆免疫球蛋白IgA、IgG、IgM浓度,采用SAS8.0统计软件进行分析。结果1.外周血单个核细胞CD4+CD30和CD4+CD30+Th的含量:HSP组分别为80.43%±1.42%和19.56%±1.42%,对照组健康儿童为89.73%±0.52%和10.26%±0.05%,t检验P<0.05,显示与健康儿童相比HSP组外周血单个核细胞CD4+CD30含量明显较高而CD4+CD30+Th明显降低。2.血浆免疫球蛋白的浓度:HSP组IgA、IgG、IgM分别为1.616±0.060g/L、10.551±1.157g/L及1.307±0.144g/L,对照组健康儿童为1.077±0.101g/L、10.597±1.283g/L及1.272±0.145g/L,显示HSP患儿血浆IgA浓度显著高于正常对照组(P<0.05),血浆IgA、IgM与正常对照组差异无显著性(P>0.05)。结论HSP患儿急性期体内存在T细胞功能紊乱,Th1和Th2的失衡,Th2细胞优势活化。血浆免疫球蛋白IgA合成异常增高。
Objective Study the immunology outbreak mechanism of HSP. Method We collected 4ml venous blood from all the children with HSP and normal. We determined the CD4^＋ CD30^＋Th/CD4^＋~ CD30^＋Th and the plasma immunoglobulin IgA, IgG, IgM by using respectively the direct immunity fluores- cence flow type cell diffusion method. All the data were determined through the positive distribution examination and analyzed with SAS 8.0 statistics software. Result 1. Th1 and Th2 content in the patients with HSP is 80. 44% ± 1.42% and 19. 56 ± 1.42%, the normal controls is 89. 73 ± 0. 52% and 10. 26 ± 0. 05%. The T test show P 〈0. 05. The rusult indicates that the content of Th2 in the patient with HSP is much higher, the content of Thl in the patient with HSP is much lower than in the heahhy chilren. 2. The plasma immunogloibulin： the concentration of IgA, IgG, IgM in the patients with HSP is 1. 616 ± 0. 060g/ L,1. 551 ± 1. 157% g/L,1. 307 ±0. 144g/L,the normal control is 1. 077±0. 101g/L,10. 597 ± 1. 283g/L, 1. 272±0. 145g/L,The T test concentration of IgA, P 〈0. 05, IgG,IgM P 〉0. 05. The result indicates that the concentration of IgA in the patient with HSP is much higher than in the healthy ehilren, IgG and IgM were not significant difference between the two groups. Conclusion The study confirm that the chilren with HSP are out of balance to some degree between Thl and Th2 and existe selectly increase in the plasma immunoglobulin IgA.
出处
《中国小儿血液与肿瘤杂志》
CAS
2006年第1期19-22,共4页
Journal of China Pediatric Blood and Cancer
基金
河北省科技指导与发展项目(42761215)
